Surgery Partners Inc. (SGRY)

Natixis Advisors L.P. Has $375,000 Position in Surgery Partners, Inc. (NASDAQ:SGRY)

Natixis Advisors L.P. raised its stake in shares of Surgery Partners, Inc. (NASDAQ:SGRY – Free Report) by 8.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,735 shares of the company’s stock after purchasing an additional 934 shares during the period. Natixis Advisors L.P.’s holdings in Surgery Partners were worth $375,000 as of its most recent SEC filing. A number of other institutional investors also recently modified their holdings of SGRY. Amalgamated Bank raised its holdings in Surgery Partners by 7.6% in the 3rd quarter. Amalgamated Bank now owns 9,948 shares of the company’s stock worth $291,000 after acquiring an additional 701 shares during the period. Raymond James & Associates lifted its position in shares of Surgery Partners by 1.2% during the 3rd quarter. Raymond James & Associates now owns 61,188 shares of the company’s stock worth $1,790,000 after purchasing an additional 736 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Surgery Partners by 69.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,945 shares of the company’s stock valued at $86,000 after purchasing an additional 1,210 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in Surgery Partners in the 3rd quarter valued at approximately $39,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Surgery Partners by 15.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,506 shares of the company’s stock worth $307,000 after buying an additional 1,387 shares during the period. Insider Buying and Selling In other Surgery Partners news, CEO Jason Eric Evans sold 4,840 shares of the business’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $29.71, for a total value of $143,796.40. Following the transaction, the chief executive officer now owns 459,670 shares of the company’s stock, valued at $13,656,795.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.60% of the stock is owned by corporate insiders. Surgery Partners Stock Performance Shares of NASDAQ:SGRY opened at $25.83 on Monday. The stock has a market capitalization of $3.28 billion, a price-to-earnings ratio of 30.76, a price-to-earnings-growth ratio of 2.04 and a beta of 2.75. The business’s fifty day moving average price is $26.82 and its two-hundred day moving average price is $30.01. Surgery Partners, Inc. has a fifty-two week low of $22.05 and a fifty-two week high of $45.79. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.71 and a quick ratio of 1.56. Surgery Partners (NASDAQ:SGRY – Get Free Report) last posted its earnings results on Monday, February 26th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. The business had revenue of $735.40 million for the quarter, compared to analyst estimates of $741.93 million. Surgery Partners had a net margin of 0.02% and a return on equity of 3.65%. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.22 EPS. As a group, analysts predict that Surgery Partners, Inc. will post 0.84 EPS for the current fiscal year. Wall Street Analysts Forecast Growth Several equities research analysts have recently issued reports on SGRY shares. StockNews.com upgraded shares of Surgery Partners from a “sell” rating to a “hold” rating in a research note on Thursday, March 21st. Royal Bank of Canada reiterated an “outperform” rating and issued a $49.00 target price on shares of Surgery Partners in a research note on Thursday, February 29th. Barclays initiated coverage on Surgery Partners in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $35.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $43.00 price objective on shares of Surgery Partners in a report on Wednesday, April 10th. Finally, Benchmark restated a “buy” rating and issued a $50.00 target price on shares of Surgery Partners in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.13. Read Our Latest Analysis on Surgery Partners Surgery Partners Profile (Free Report) Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.